Recaticimab - CAS 2361290-85-7

Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9. By binding to PCSK9, Recaticimab promotes LDL receptor stabilization and surface expression on hepatocytes, leading to reduced plasma LDL cholesterol levels. Recaticimab is under study as a therapeutic candidate for hypercholesterolemia and related cardiovascular disorders.

LDLR, Others

Metabolism, Others

2361198

0.997

-20°C

Ice Packs

Inhibitory Antibodies